Cholinergic modulation of amyloid precursor protein processing with emphasis on M1 muscarinic receptor: perspectives and challenges in treatment of Alzheimer's disease.
Abraham Fisher
https://pubmed.ncbi.nlm.nih.gov/22122190/Actively Recruiting
Led by NSC-Therapeutics · Updated on 2026-04-17
90
Participants Needed
10
Research Sites
8 weeks
Total Duration
This research aims to evaluate the safety and tolerability of NSC001, an experimental drug, in people aged 50 to 85 years with mild to moderate Alzheimers disease. NSC001 is designed to target specific brain receptors to potentially improve cognitive and behavioral functions. The study is a randomized, double-blind, placebo-controlled trial conducted across multiple centers to explore both safety and effects on cognition and behavior. Participants will be randomly assigned to one of three groups receiving 40 mg of NSC001 daily, 40 mg of NSC001 daily combined with 20 mg of Trospium, or a placebo with or without 20 mg of Trospium. Treatment and monitoring will occur over 16 weeks, with assessments of drug levels in the blood at specific times. The study includes careful safety monitoring and evaluation of cognitive function throughout the trial. During the study, participants and their caregivers will attend scheduled visits for physical, cognitive, and behavioral assessments. Brain imaging such as MRI or CT scans will be reviewed if available, and tests to confirm Alzheimers diagnosis will be done. Researchers will track medication adherence, collect blood samples, and monitor safety and tolerability. The primary outcomes focus on safety at the start and end of treatment, while secondary measures analyze how the drug behaves in the body over time.
CONDITIONS
A Study to Assess Safety and Tolerability and to Explore Efficacy of NSC001 in Mild to Moderate Alzheimer's Disease
B
Barbara Fridrich, DI
K
Klara Fuereder, MSC
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
NSC-Therapeutics
Lead Sponsor
NeuroScios GmbH
Collaborating Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - 16 weeks
Participants receive NSC001 or placebo daily to assess safety, tolerability, and exploratory efficacy in mild to moderate Alzheimer's Disease.
Multiple visits including visits at weeks 0, 1, 2, 3, 4, and 16 to assess safety and drug concentration
Study Type
INTERVENTIONAL
Masking
TRIPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
3
Have more questions? Get in touch with our team for quick support
Abraham Fisher
https://pubmed.ncbi.nlm.nih.gov/22122190/Abraham Fisher
https://pubmed.ncbi.nlm.nih.gov/18625455/NSC-Therapeutics
Lead Sponsor
NeuroScios GmbH
Collaborating Sponsor